Several investigational agents targeting the NLRP3 inflammasome or its downstream effectors have already shown encouraging results in non - renal diseases (291); however, research evaluating their efficacy specifically in kidney pathologies remains limited. The gene discussed is NLRP3; the disease is urogenital neoplasm.